

SOME FUCKING TITLE

SDIV, FPA, DGS, GASV

ABSTRACT. BACKGROUND. CONTRIBUTION. IMPLICATIONS-

1. INTRODUCTION

2. MODEL FORMULATION

Uncontrolled dynamics. We split the the constant population N in a base SEIR structure with segregation infected classes according with manifestation of symptoms. We also propouse the extra state CI_s to fit data from Mexico city in the exponential grow phase. The dynamics reads

$$\begin{aligned}
 (1) \quad & L' = -\epsilon\lambda L - \delta_L L - \mu L, \\
 & S' = \mu N^* + \delta_L - (\lambda + \mu)S, \\
 & E' = \lambda(\epsilon L + S) - (\kappa + \mu)E, \\
 & I_S' = p\kappa E - (\gamma_S + \delta_H + \mu_{I_S} + \mu)I_S, \\
 & I_A' = (1 - p)\kappa E - \gamma_A I_A - \mu I_A, \\
 & H' = \delta_H I_S - (\gamma_H + \mu_H)H - \delta_H H - \mu H, \\
 & R' = \gamma_S I_S + \gamma_A I_A + \gamma_H H - \mu R, \\
 & D' = \mu_{I_S} I_S + \mu_H H, \\
 & \frac{d}{dt} CI_S = p\kappa E, \\
 & \lambda := \frac{\beta_A I_A + \beta_S I_S}{N^*}, \\
 & N^*(t) = L + S + E + I_S + I_A + H + R.
 \end{aligned}$$

See table[*] for notation and values.

Hypothesis. We consider that susceptible individuals become infected when they are in contact with asymptomatic individuals and individuals with symptoms, we will propose that a proportion of asymptomatic individuals have a way to get relief and not die. A proportion of individuals infected with symptoms may die from the disease or may be relieved.

We callibrate parameters of our base dynamics in (1) via Multichain Montecarlo (MCMC). To this end, we assume that the comulative incidence of new infected symptomatic cases CI_S follows a Poisson distribution with mean $\lambda_t = IC_s(t)$. Further, following [] we postulate priors for p and κ

$$\begin{aligned}
 (2) \quad & Y_t \sim Poisson(\lambda_t), \\
 & \lambda_t = \int_0^t p \delta_e E, \\
 & p \sim Uniform(0.3, 0.8), \\
 & \kappa \sim Gamma(10, 50).
 \end{aligned}$$

Ussing the reproductive number definition of VanDenDrishe, we obtain

$$R_0 := \frac{N^*(\beta_S p \kappa + \beta_A \kappa (1 - p))}{(\mu - \kappa)(\gamma_S + \mu_{I_S} + S_A + \mu)N^* \mu}$$

Figure [...] displays data of coumulative confirmed cases of COVID-19 of Mexico city, and the fitt of our model in eqs. (1) and (2).
Controlled Model. We model vaccination, treatment and lockdown as a optimal control problem.

3. SEIR VERSION

Here we propose a SEIR structure which considers hospitalized compartment H . To overcome stability issues we also consider vital dynamics.

$$\begin{aligned} \min_{u \in \mathcal{U}} &= \int_0^T \left(a_{I_S} I_S + a_H H + a_D D + \frac{a_L}{2} u_L^2 + \frac{a_V}{2} u_V^2 + \frac{a_H}{2} u_H^2 + \frac{a_M}{2} u_M^2 \right) dt \\ \text{s. t.} & \\ L' &= -\epsilon \lambda L - u_L(t) L - \mu L \\ S' &= \mu N^* + u_L(t) L + (1 - \hat{q}) \gamma_V V - \lambda S - u_V(t) S - \mu S \\ E' &= \lambda(\epsilon L + S) - \kappa E - \mu E \\ I_S' &= p \kappa E - (\gamma_S + \mu_{I_S} + \delta_H) I_S - u_M(t) I_S + (1 - q) \gamma_M M(t) - \mu I_S \\ I_A' &= (1 - p) \kappa E - \gamma_A I_A - \mu I_A \\ M' &= u_M(t) I_S - \gamma_M M - \mu M \\ H' &= \delta_H I_S - (\gamma_H + \mu_H) H - \mu H \\ R' &= \gamma_S I_S + \gamma_A I_A + \gamma_H H + q \gamma_M M + \hat{q} \gamma_V V - \mu R \\ D' &= \mu_{I_S} I_S + \mu_H H \\ V' &= \delta_S - \gamma_V V - \mu V \\ \lambda &:= \frac{\beta_A I_A + \beta_S I_S}{N^*} \\ N^*(t) &= L + S + E + I_S + I_A + M + H + R + V \end{aligned} \tag{3}$$

Bayesian estimation.

4. PARAMETERS

5. OPTIMAL CONTROL PROBLEM

6. NUMERICAL RESULTS

Bayesian.

7. APPENDIX

Consider the following cost functional that we want to minimize

$$(4) \quad \int_0^T C(t, X(t), u(t)) dt$$

subject to the dynamics

$$(5) \quad \dot{X}(t) = f(t, X(t), u(t)), \quad 0 \leq t \leq T,$$

and the initial state $X(0) = x_0$. Let $t_0 < t_1 < \dots < t_n$, with $t_0 = 0$ and $t_n = T$, be a partition of the interval $[0, T]$. We consider *piecewise constant controls* \tilde{u} of the form

$$(6) \quad \tilde{u}(t) = a_j \quad t_j \leq t < t_{j+1}$$

Parameter	Median	Reference
β_S	$8.690\,483 \times 10^{-1}$	*
β_A	$7.738\,431 \times 10^{-1}$	*
κ	$2.143\,749 \times 10^{-1}$	*
p	$4.387\,130 \times 10^{-1}$	*
δ_H	$4.603\,172 \times 10^{-1}$	*
μ	0.000039139	**
μ_{I_S}	$5.691\,990 \times 10^{-2}$	*
μ_H	$3.280\,390 \times 10^{-2}$	*
γ_S	$1.197\,828 \times 10^{-1}$	*
γ_A	$5.113\,880 \times 10^{-1}$	*
γ_H	$4.880\,279 \times 10^{-1}$	*
N	8 918 653	**
S_0	$N - (E_0 + I_{S_0} + I_{A_0})$	
E_0	1388	*
I_{S_0}	22	* * *
I_{A_0}	1595	*
H_0	0	**
R_0	0	**
D_0	0	**

for $j = 0, \dots, n-1$.

ASSUMPTION 1.

ASSUMPTION 2.

By Assumption 1, the system

$$\dot{X}(t) = f(t, X(t), a_0), \quad X(0) = x_0, \quad 0 \leq t \leq t_1,$$

has a unique solution $\tilde{X}_0(t; x_0, a_0)$ which is continuous in (x_0, a_0) . Next, put $x_1 := \tilde{X}_0(t_1; x_0, a_0)$ and consider the system

$$\dot{X}(t) = f(t, X(t), a_1), \quad X(t_1) = x_1, \quad t_1 \leq t \leq t_2,$$

which, again by Assumption 1, has a unique solution $\tilde{X}_1(t; x_1, a_1)$ continuous in (x_1, a_1) . By following this procedure, we end up having a recursive solution

$$\tilde{X}_{n-1}(t; x_{n-1}, a_{n-1}), \quad x_{n-1} := \tilde{X}_{n-2}(t_{n-1}; x_{n-2}, a_{n-1}), \quad t_{n-1} \leq t \leq T.$$

Thus, for a control \tilde{u} of the form (6) and the corresponding solution path \tilde{X} , we have

$$\int_0^T C(t, \tilde{X}(t), \tilde{u}(t)) dt = \sum_{j=0}^{n-1} \int_{t_j}^{t_{j+1}} C(t, \tilde{X}_j(t), a_j) dt.$$

Notice that each \tilde{X}_j is a continuous function of (a_0, \dots, a_j) and x_0 . Therefore, by Assumption 2, the mapping

$$(a_0, \dots, a_{n-1}) \mapsto \sum_{j=0}^{n-1} \int_{t_j}^{t_{j+1}} C(t, \tilde{X}_j(t), a_j) dt$$

is continuous.

REFERENCES

- [1] Yinon M Bar-on, Ron Sender, Avi I Flamholz, Rob Phillips, and Ron Milo. A quantitative compendium of COVID-19 epidemiology. pages 1–51.

- [2] Bruno Buonomo. Effects of information-dependent vaccination behavior on coronavirus outbreak: insights from a SIRI model. *Ricerche di Matematica*, 2020.
- [3] Anastasia Chatzilela, Edwin van Leeuwen, Oliver Ratmann, Marc Baguelin, and Nikolaos Demiris. Contemporary statistical inference for infectious disease models using Stan. *Epidemics*, 29(February):100367, 2019.
- [4] Nicholas G Davies, Adam J Kucharski, Rosalind M Eggo, Amy Gimma, CMMID COVID-19 Working Group, and W. John Edmunds. The effect of non-pharmaceutical interventions on COVID-19 cases, deaths and demand for hospital services in the UK: a modelling study. *medRxiv*, page 2020.04.01.20049908, 2020.
- [5] Laura Di Domenico, Giulia Pullano, Chiara E Sabbatini, Pierre-Yves Boëlle, and Vittoria Colizza. Currently under screening at medRxiv Expected impact of lockdown in Île-de-France and possible exit strategies. 2020.
- [6] Wandu Ding and Suzanne Lenhart. Introduction to optimal control for discrete time models with an application to disease modeling. In *Modeling paradigms and analysis of disease transmission models*, volume 75, pages 109–119. Amer. Math. Soc., Providence, RI, oct 2010.
- [7] Ramses Djidjou-Demasse, Yannis Michalakis, Marc Choisy, Micea T. Sofonea, and Samuel Alizon. Optimal COVID-19 epidemic control until vaccine deployment. *medRxiv*, page 2020.04.02.20049189, 2020.
- [8] Neil M Ferguson, Daniel Laydon, Gemma Nedjati-gilani, Natsuko Imai, Kylie Ainslie, Marc Baguelin, Sangeeta Bhatia, Adhiratha Boonyasiri, Zulma Cucunubá, Gina Cuomo-dannenburg, Amy Dighe, Han Fu, Katy Gaythorpe, Will Green, Arran Hamlet, Wes Hinsley, Lucy C Okell, Sabine Van, Hayley Thompson, Robert Verity, Erik Volz, Haowei Wang, Yuanrong Wang, Patrick G T Walker, Caroline Walters, Peter Winskill, Charles Whittaker, Christl A Donnelly, Steven Riley, and Azra C Ghani. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID- 19 mortality and healthcare demand. (March), 2020.
- [9] M. H. A. Biswas, L. T. Paiva, and MdR de Pinho. A SEIR model for control of infectious diseases with constraints. *Mathematical Biosciences and Engineering*, 11(4):761–784, 2014.
- [10] IHME COVID-19 health service utilization forecasting Team and Christopher JL Murray. Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator-days and deaths by US state in the next 4 months. *medRxiv*, page 2020.03.27.20043752, mar 2020.
- [11] Gang Huang, Yasuhiro Takeuchi, Wanbiao Ma, and Daijun Wei. Global Stability for Delay SIR and SEIR Epidemic Models with Nonlinear Incidence Rate. *Bulletin of Mathematical Biology*, 72(5):1192–1207, 2010.
- [12] Jiwei Jia, Jian Ding, Siyu Liu, Guidong Liao, Jingzhi Li, B. E.N. Duan, Guoqing Wang, and R. A.N. Zhang. Modeling the control of COVID-19: Impact of policy interventions and meteorological factors. *Electronic Journal of Differential Equations*, 2020:1–21, 2020.
- [13] Abdelilah Kaddar, Abdelhadi Abta, and Hamad Talibi Alaoui. A comparison of delayed SIR and SEIR epidemic models. *Nonlinear Analysis: Modelling and Control*, 16(2):181–190, apr 2011.
- [14] Qian Li, Biao Tang, Nicola Luigi Bragazzi, Yanni Xiao, and Jianhong Wu. Modeling the impact of mass influenza vaccination and public health interventions on COVID-19 epidemics with limited detection capability. *Mathematical Biosciences*, 325(May):108378, jul 2020.

- [15] Gustavo Barbosa Libotte, Fran Sérgio Lobato, Gustavo Mendes Platt, and Antônio José da Silva Neto. Determination of an Optimal Control Strategy for Vaccine Administration in COVID-19 Pandemic Treatment. (November 2019), apr 2020.
- [16] Manotosh Mandal, Soovoojeet Jana, Swapan Kumar Nandi, Anupam Khatua, Sayani Adak, and T.K. Kar. A model based study on the dynamics of COVID-19: Prediction and control. *Chaos, Solitons & Fractals*, 136:109889, jul 2020.
- [17] Van Kinh Nguyen and Esteban A. Hernandez-Vargas. Parameter Estimation in Mathematical Models of Viral Infections Using R. volume 1836, pages 531–549. 2018.
- [18] Jorge Nocedal, Andreas Wächter, and Richard A. Waltz. Adaptive Barrier Update Strategies for Nonlinear Interior Methods. *SIAM Journal on Optimization*, 19(4):1674–1693, jan 2009.
- [19] Xinwei Wang, Haijun Peng, Boyang Shi, Dianheng Jiang, Sheng Zhang, and Biaosong Chen. Optimal vaccination strategy of a constrained time-varying SEIR epidemic model. *Communications in Nonlinear Science and Numerical Simulation*, 67:37–48, 2019.